PYGO2

PYGO2 is a PHD finger-containing chromatin effector that reads H3K4me2/3 marks and recruits histone H3 K4 methyltransferase complexes to promote H3K4 trimethylation at target loci, functioning as a context-dependent coactivator of the Wnt/β-catenin–TCF transcriptional complex through association with BCL9/BCL9-2 (PMID:19487454, PMID:27811361). Beyond canonical Wnt signaling, PYGO2 has β-catenin-independent roles in spermatid chromatin remodeling—where it drives histone H3 hyperacetylation required for protamine expression (PMID:18614164)—and suppresses Notch3 transcription in mammary stem/basal cells to restrain luminal differentiation (PMID:23684539). PYGO2 protein stability is controlled by Akt-mediated Ser48 phosphorylation opposing Cul4-DDB1 E3 ligase-dependent ubiquitylation, and CBP/p300-mediated acetylation of its nuclear localization signal drives nuclear-to-cytoplasmic recycling after transcriptional activation (PMID:26170450, PMID:27647933). In the tumor microenvironment PYGO2 orchestrates a p53/Sp1/Kit/Ido1 network that suppresses cytotoxic T-cell infiltration, and its deletion sensitizes prostate tumors to immune checkpoint blockade (PMID:36897957).

1. 2007 High

   Establishing that mammalian Pygo2 is a quantitative modulator rather than an essential on/off switch of Wnt/β-catenin signaling resolved whether the obligate requirement seen in Drosophila is conserved, revealing tissue-specific sensitivity in kidney branching morphogenesis.

   Evidence Pygo2 null mice with BAT-gal Wnt reporter and confocal/microarray analysis

   PMID:17425782

   Open questions at the time

   • Molecular mechanism by which Pygo2 modulates Wnt output not defined
   • Redundancy with Pygo1 not fully dissected
   • No direct chromatin-level mechanism identified
2. 2008 High

   Demonstrating that Pygo2 is required for histone H3 hyperacetylation and protamine/transition protein expression in spermatids established a β-catenin-independent chromatin-remodeling function, fundamentally expanding the gene's functional repertoire beyond Wnt signaling.

   Evidence Hypomorphic mouse alleles with spermatid histological and histone acetylation analysis

   PMID:18614164

   Open questions at the time

   • Identity of the acetyltransferase recruited by Pygo2 in spermatids unknown
   • Whether the PHD domain mediates this function not tested
   • No structural basis for β-catenin-independent chromatin binding
3. 2009 High

   Identifying Pygo2 as an H3K4me reader that recruits H3K4 methyltransferase complexes provided the first direct biochemical mechanism linking Pygo2's PHD finger to epigenetic mark propagation and mammary progenitor expansion.

   Evidence ChIP, direct histone binding assays, epithelia-specific and complete KO mice, mammary transplantation

   PMID:19487454

   Open questions at the time

   • Specific methyltransferase complex identity not determined
   • Whether H3K4me reading and Wnt co-activation are separable activities unclear
   • No structural resolution of PHD–H3K4me interaction in mammalian Pygo2
4. 2013 High

   Showing that Pygo2 suppresses Notch3 transcription in mammary stem cells and delays Wnt1-driven tumor onset established it as a chromatin-state gatekeeper at the Wnt–Notch signaling interface, explaining how it controls cell-fate decisions beyond simple Wnt target activation.

   Evidence Epithelia-specific KO in normal and MMTV-Wnt1 mice, ChIP at Notch3, transplantation, Notch pathway manipulation

   PMID:23334328 PMID:23684539

   Open questions at the time

   • Mechanism by which Pygo2 maintains poised/repressed state at Notch3 not fully resolved
   • Whether Pygo2-Notch3 axis operates outside mammary tissue untested
5. 2014 High

   Linking Pygo2 and β-catenin to p53 accumulation and acetylation during hair follicle progenitor cell cycle entry revealed a convergence between Wnt signaling and the p53 pathway, identifying a new downstream effector axis.

   Evidence Epithelia-specific KO mice, depilation and skin hyperplasia models, cultured keratinocytes

   PMID:24982158

   Open questions at the time

   • Whether Pygo2 acts on p53 directly or through intermediate chromatin targets unknown
   • Functional consequence of p53 acetylation in this context not determined
6. 2015 High

   Identifying Cul4-DDB1 as the E3 ligase for Pygo2 degradation and Akt-mediated Ser48 phosphorylation as a stabilizing signal defined the post-translational control circuit governing Pygo2 protein levels.

   Evidence Co-IP with Cul4/DDB1, ubiquitylation assays, Ser48 mutagenesis, proteasome inhibitor treatment

   PMID:26170450

   Open questions at the time

   • DDB1-associated substrate receptor (DCAF) not identified
   • In vivo validation of the Akt-Pygo2 stability axis not shown
   • Interplay between phosphorylation and acetylation-based recycling unknown
7. 2016 High

   Demonstrating CBP/p300-mediated acetylation of Pygo2's NLS lysines and consequent nuclear export established a post-activation recycling mechanism and revealed how Pygo2 is cleared from active TCF/β-catenin complexes, while parallel work defined the BCL9/β-catenin/Pygo2 complex as a coactivator of c-Myc in intestinal tumorigenesis.

   Evidence In vitro acetyltransferase assays, NLS lysine mutagenesis, subcellular fractionation; Pygo2 KO in chemical carcinogenesis and Ctnnb1 GOF/Apc LOF mouse models

   PMID:26876203 PMID:27647933 PMID:27811361

   Open questions at the time

   • Deacetylase responsible for reversing NLS acetylation not identified
   • Whether nuclear export requires exportin machinery or passive diffusion unknown
   • Reason Pygo2 loss does not affect Apc LOF tumors mechanistically unexplained
8. 2018 High

   Defining Pygo2 as a driver oncogene at the 1q21.3 amplicon in prostate cancer and uncovering a Wnt-independent role in adipogenesis via the Axin2/GSK3β/C/EBPβ axis broadened PYGO2's functional scope to metabolic regulation and cancer genomics.

   Evidence In vivo tumorigenesis screens with PDX models; adipocyte-specific KO mice with nuclear fractionation and glucose tolerance tests

   PMID:29769196 PMID:30279163

   Open questions at the time

   • Whether the Axin2/GSK3β pathway is a direct transcriptional target of Pygo2 or secondary to Wnt modulation not resolved
   • Structural basis for Pygo2 oncogenic gain-of-function at 1q21.3 undetermined
9. 2023 High

   Revealing that Pygo2 drives immune evasion through a p53/Sp1/Kit/Ido1 network suppressing CTL infiltration, and identifying BRPF1 as a direct transcriptional target in colorectal cancer, opened new therapeutic vulnerabilities.

   Evidence Transgenic metastatic prostate cancer models with Pygo2 deletion, flow cytometry, adoptive transfer, ICB treatment; ChIP-qPCR at BRPF1 promoter, BRPF1 inhibitor in vivo

   PMID:36897957 PMID:37423512

   Open questions at the time

   • Whether the Kit/Ido1 axis is a direct Pygo2 chromatin target or downstream of p53 not fully resolved
   • BRPF1 dependency in non-colorectal Pygo2-high cancers not tested
   • No pharmacological Pygo2 inhibitor validated

• Key open questions remain: the identity of the specific H3K4 methyltransferase complex recruited by Pygo2, the structural basis of its PHD–H3K4me interaction in mammals, how its phosphorylation and acetylation codes are integrated to control its activity and localization, and whether its immune-modulatory and chromatin-remodeling roles converge mechanistically.
• No structural model of mammalian Pygo2 PHD–histone interaction
• Integration of Akt phosphorylation and CBP/p300 acetylation signals not addressed
• Pharmacological inhibition of Pygo2 not achieved